|Bid||0.8600 x 0|
|Ask||0.8800 x 0|
|Day's Range||0.8700 - 0.8800|
|52 Week Range||0.2500 - 1.1600|
|Beta (5Y Monthly)||-0.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 14, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.10|
RICHMOND HILL, ON / ACCESSWIRE / June 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Heman Chao has notified the Board of Directors of the Company of his intention to step down from the position of Chief Executive Officer ("CEO"), Chief Scientific Officer ("CSO") and member of the Board, effective September 1, 2021.
RICHMOND HILL, ON / ACCESSWIRE / June 24, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has appointed Marcum LLP as the Company's new auditor, replacing BDO Canada LLP.
By John Vandermosten, CFA TSX:HBP.TO | OTC:HBPCF READ THE FULL HBP.TO RESEARCH REPORT Helix BioPharma Corp. (TSX:HBP.TO) (OTC:HBPCF) reported 3Q:21 financial and operational results and submitted its SEDAR filings on June 14, 2021. During 3Q:21, the three months ended April 30, 2021, Helix appointed Dr. Frank Gary Renshaw to the Scientific Advisory Board, and extended the exercise period for